Literature DB >> 21471648

Does adaptive cognitive testing combine efficiency with precision? Prospective findings.

Hans Wouters1, Jos van Campen, Bregje Appels, Robert Lindeboom, Maarten Buiter, Rob J de Haan, Aeilko H Zwinderman, Willem A van Gool, Ben Schmand.   

Abstract

Longer cognitive tests, such as the Alzheimer's disease assessment scale (ADAS-cog) or the Cambridge cognitive examination (CAMCOG), are more precise but less efficient than briefer tests, such as the Mini Mental State Examination (MMSE). We examined if computerized adaptive testing (CAT) of cognitive impairment can combine brevity with precision by tailoring a precise test to each individual patient. We conducted a prospective study of 84 participants [normal aging, n = 41; mild cognitive impairment (MCI), n = 21; dementia, n = 22]. CAT estimated a participant's ability during testing by selecting only items of appropriate difficulty from either the CAMCOG or the CAMCOG supplemented with ADAS-cog items and neuropsychological tests (the CAMCOG-Plus). After tailored testing with CAT, the remaining CAMCOG and CAMCOG-Plus items not selected by CAT were administered. The time needed to complete the CAT was compared to that needed for the whole CAMCOG and CAMCOG-Plus. Results showed that testing time reductions achieved with CAT were 37% or more compared to the whole CAMCOG and 55% or more compared to the whole CAMCOG-Plus. Estimated ability levels with CAT were in excellent agreement with those based on the whole CAMCOG and CAMCOG-Plus (intraclass correlations 0.99 and 0.98, respectively). Diagnostic accuracy of detecting mild dementia and MCI seemed better for the CAT administered tests than for the MMSE, but the differences were not significant. We conclude that adaptive testing combines brevity with precision, especially in grading the severity of cognitive impairment.

Entities:  

Mesh:

Year:  2011        PMID: 21471648     DOI: 10.3233/JAD-2011-101743

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  7 in total

1.  Individualized evaluation of cholinesterase inhibitors effects in dementia with adaptive cognitive testing.

Authors:  Hans Wouters; Jos P C M Van Campen; Bregje A Appels; Jos H Beijnen; Aeilko H Zwinderman; Willem A Van Gool; Ben Schmand
Journal:  Int J Methods Psychiatr Res       Date:  2015-08-24       Impact factor: 4.035

Review 2.  Applications of technology in neuropsychological assessment.

Authors:  Carolyn M Parsey; Maureen Schmitter-Edgecombe
Journal:  Clin Neuropsychol       Date:  2013-09-16       Impact factor: 3.535

3.  Assessment of self-reported negative affect in the NIH Toolbox.

Authors:  Paul A Pilkonis; Seung W Choi; John M Salsman; Zeeshan Butt; Tara L Moore; Suzanne M Lawrence; Nicholas Zill; Jill M Cyranowski; Morgen A R Kelly; Sarah S Knox; David Cella
Journal:  Psychiatry Res       Date:  2012-10-22       Impact factor: 3.222

4.  Screening for Mild Cognitive Impairment and Dementia with Automated, Anonymous Online and Telephone Cognitive Self-Tests.

Authors:  Lisa D Van Mierlo; Hans Wouters; Sietske A M Sikkes; Wiesje M Van der Flier; Niels D Prins; Jonne A E Bremer; Teddy Koene; Hein P J Van Hout
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 5.  The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review.

Authors:  Jacqueline K Kueper; Mark Speechley; Manuel Montero-Odasso
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 6.  Digital Cognitive Biomarker for Mild Cognitive Impairments and Dementia: A Systematic Review.

Authors:  Zihan Ding; Tsz-Lok Lee; Agnes S Chan
Journal:  J Clin Med       Date:  2022-07-19       Impact factor: 4.964

7.  Can the Virtual Reality-Based Spatial Memory Test Better Discriminate Mild Cognitive Impairment than Neuropsychological Assessment?

Authors:  Jin-Hyuck Park
Journal:  Int J Environ Res Public Health       Date:  2022-08-12       Impact factor: 4.614

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.